Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients (Q34141845)

31 July 2017

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients (English)

1 reference

31 July 2017

0 references

1 reference

1 reference

1 reference

7

Francois Clavel

1 reference

31 July 2017

1

Anne-Marie Taburet

1 reference

31 July 2017

2

Christophe Piketty

1 reference

31 July 2017

3

Corine Chazallon

1 reference

31 July 2017

8

Jean-Pierre Aboulker

1 reference

31 July 2017

9

Pierre-Marie Girard

1 reference

31 July 2017

Isabelle Vincent

4

1 reference

31 July 2017

Laurence Gérard

series ordinal

5

1 reference

31 July 2017

Vincent Calvez

series ordinal

6

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Antimicrobial Agents and Chemotherapy

31 July 2017

1 reference

31 July 2017

48

1 reference

31 July 2017

2091-2096

1 reference

31 July 2017

6

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

31 July 2017

1 reference

A review of low-dose ritonavir in protease inhibitor combination therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

Role of P-glycoprotein in pharmacokinetics: clinical implications

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

Principles and practice of HIV-protease inhibitor pharmacoenhancement

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography–tandem mass spectrometry following automated solid-phase extraction

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

Daily dosing of highly active antiretroviral therapy.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=415627

Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus

28 October 2018

1 reference

12 December 2020

Tenofovir disoproxil fumarate

1 reference

12 December 2020

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

1 reference

12 December 2020

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884

1 reference

12 December 2020

10.1128/AAC.48.6.2091-2096.2004

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference